2026-04-11T11:07:38Z
https://pub.unibl.org/oai
oai:pub.unibl.org:40237
2024-06-12T14:22:23Z
3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study
/unibl/author/Josef S Smolen
/unibl/author/Jung Yoon Choe
/unibl/author/Nenad Prodanović
/unibl/author/Y.H, Rho
2017
Academic Article
text
10
10
/unibl/sci/idNaucniRad:25128
ANNALS OF THE RHEUMATIC DISEASES
0003-4967
ANNALS OF THE RHEUMATIC DISEASES
0003-4967
J. Smolen, J. Choe, N. Prodanović, Y. Rho, 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2017